J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech assetnews2022-02-02T21:58:05+00:00February 2nd, 2022|FierceBiotech|
J&J’s Janssen inks $1B biobucks pact for Mersana’s ADC tech in 3 targetsnews2022-02-02T21:20:14+00:00February 2nd, 2022|FierceBiotech|
Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on tracknews2022-02-02T14:33:46+00:00February 2nd, 2022|FierceBiotech|
FDA puts LogicBio genome editing therapy trial on hold after 2nd infant suffers adverse eventnews2022-02-02T12:54:26+00:00February 2nd, 2022|FierceBiotech|
Novartis JAKs in rival to Incyte’s topical eczema drug after seeing clinical datanews2022-02-02T10:26:49+00:00February 2nd, 2022|FierceBiotech|
Doctor groups urge Biden administration to disclose costs of federally funded clinical trialsnews2022-02-01T15:27:23+00:00February 1st, 2022|FierceBiotech|
Anavex touts ‘very large’ phase 3 win for Rett syndrome drug—2 weeks after moving study’s goalpostsnews2022-02-01T15:27:06+00:00February 1st, 2022|FierceBiotech|
UPDATE: Anavex touts ‘very large’ phase 3 win for Rett syndrome drug—2 weeks after moving study’s goalpostsnews2022-02-01T15:27:06+00:00February 1st, 2022|FierceBiotech|
Takeda shunts jewel of Shire takeover to new spinoff Oak Hillnews2022-02-01T13:21:06+00:00February 1st, 2022|FierceBiotech|
As CEO goes, cash woes drive Sio to give Parkinson’s program the heave-honews2022-02-01T10:19:37+00:00February 1st, 2022|FierceBiotech|
